Clinical Trial Update: A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients [Phase 1]

View source ↗

Summary

This Phase 1 trial update evaluates safety, tolerability, and plasma concentrations of ND0612, a levodopa/carbidopa subcutaneous formulation, in Parkinson's dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ND0612 Levodopa/Carbidopa Subcutaneous Solution (Levodopa/Carbidopa subcutaneous formulation)

Snippet

Sponsor: NeuroDerm Ltd. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED